Manufacturer of Controlled Substances; Notice of Application; Noramco, Inc. (GA), 37241-37242 [2013-14458]
Download as PDF
<![CDATA[
37241
Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices
Basic class
Meperidine Intermediate—A .................................................................................................................................
Meperidine Intermediate—B .................................................................................................................................
Meperidine Intermediate—C .................................................................................................................................
Metazocine ............................................................................................................................................................
Methadone (for sale) ............................................................................................................................................
Methadone Intermediate .......................................................................................................................................
Methamphetamine ................................................................................................................................................
6
11
6
6
25,000,000
32,500,000
3,912,500
Proposed or
proposed
adjusted
2013 quotas
Previously
established
2013 quotas
g
g
g
g
g
g
g
No change.
No change.
No change.
No change.
33,125,000 g.
40,500,000 g.
No change.
[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly
for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)]
Methylphenidate ....................................................................................................................................................
Morphine (for conversion) .....................................................................................................................................
Morphine (for sale) ...............................................................................................................................................
Nabilone ................................................................................................................................................................
Noroxymorphone (for conversion) ........................................................................................................................
Noroxymorphone (for sale) ...................................................................................................................................
Opium (powder) ....................................................................................................................................................
Opium (tincture) ....................................................................................................................................................
Oripavine ...............................................................................................................................................................
Oxycodone (for conversion) .................................................................................................................................
Oxycodone (for sale) ............................................................................................................................................
Oxymorphone (for conversion) .............................................................................................................................
Oxymorphone (for sale) ........................................................................................................................................
Pentobarbital .........................................................................................................................................................
Phenazocine .........................................................................................................................................................
Phencyclidine ........................................................................................................................................................
Phenmetrazine ......................................................................................................................................................
Phenylacetone ......................................................................................................................................................
Racemethorphan ..................................................................................................................................................
Remifentanil ..........................................................................................................................................................
Secobarbital ..........................................................................................................................................................
Sufentanil ..............................................................................................................................................................
Tapentadol ............................................................................................................................................................
Thebaine ...............................................................................................................................................................
80,750,000
103,750,000
60,250,000
25,628
9,000,000
508,750
91,250
1,287,500
22,750,000
10,250,000
131,500,000
18,375,000
6,875,000
42,500,000
6
30
3
20,000,000
3
3,750
215,003
6,255
13,750,000
145,000,000
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
96,750,000 g.
91,250,000 g.
No change.
No change.
No change.
1,262,500 g.
No change.
No change.
No change.
No change.
153,750,000 g.
No change.
No change.
No change.
No change.
No change.
No change.
29,628,750 g.
No change.
No change.
No change.
No change.
No change.
No change.
15,100,000
3,500,000
25,700,000
6,100,000
225,000,000
g
g
g
g
g
No
No
No
No
No
List I Chemicals
Ephedrine (for conversion) ...................................................................................................................................
Ephedrine (for sale) ..............................................................................................................................................
Phenylpropanolamine (for conversion) .................................................................................................................
Phenylpropanolamine (for sale) ............................................................................................................................
Pseudoephedrine (for sale) ..................................................................................................................................
The Deputy Administrator further
proposes that aggregate production
quotas for all other schedule I and II
controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero. Pursuant to 21 CFR 1303.13 and 21
CFR 1315.13, upon consideration of the
relevant factors, the Deputy
Administrator may adjust the 2013
aggregate production quotas and
assessment of annual needs as needed.
TKELLEY on DSK3SPTVN1PROD with NOTICES
Comments
Pursuant to 21 CFR 1303.11 and 21
CFR 1315.11, any interested person may
submit written comments on or
objections to these proposed
determinations. Based on comments
received in response to this Notice, the
Deputy Administrator may hold a
public hearing on one or more issues
raised. In the event the Deputy
Administrator decides in his sole
VerDate Mar<15>2010
17:01 Jun 19, 2013
Jkt 229001
discretion to hold such a hearing, the
Deputy Administrator will publish a
notice of any such hearing in the
Federal Register. After consideration of
any comments and after a hearing, if one
is held, the Deputy Administrator will
publish in the Federal Register a Final
Order establishing any adjustment of
2013 aggregate production quota for
each basic class of controlled substance
and assessment of annual needs for the
list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
Dated: June 14, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013–14723 Filed 6–19–13; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
change.
change.
change.
change.
change.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Noramco, Inc. (GA)
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 21, 2012,
Noramco, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Opium tincture
(9630), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
E:\FR\FM\20JNN1.SGM
20JNN1
37242
Federal Register / Vol. 78, No. 119 / Thursday, June 20, 2013 / Notices
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administrator, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 19, 2013.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (NIJ) Docket No. 1624]
Draft Report and Recommendations
Prepared by the Research Committee
of the Scientific Working Group on
Medicolegal Death Investigation
National Institute of Justice,
DOJ.
Notice and request for
comments.
ACTION:
In an effort to obtain
comments from interested parties, the
U.S. Department of Justice, Office of
Justice Programs, National Institute of
Justice, Scientific Working Group for
Medicolegal Death Investigation will
make available to the general public a
document entitled, ‘‘Research in
Forensic Pathology/Medicolegal Death
Investigation’’. The opportunity to
provide comments on this document is
open to coroner/medical examiner office
representatives, law enforcement
agencies, organizations, and all other
stakeholders and interested parties.
Those individuals wishing to obtain and
provide comments on the draft
document under consideration are
directed to the following Web site:
https://www.swgmdi.org.
DATES: Comments must be received on
or before July 29, 2013.
FOR FURTHER INFORMATION CONTACT:
Patricia Kashtan, by telephone at 202–
353–1856 [Note: this is not a toll-free
telephone number], or by email at
Patricia.Kashtan@usdoj.gov.
TKELLEY on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Greg Ridgeway,
Acting Director, National Institute of Justice.
[FR Doc. 2013–14707 Filed 6–19–13; 8:45 am]
BILLING CODE 4410–18–P
VerDate Mar<15>2010
17:01 Jun 19, 2013
Jkt 229001
Request for Public Comments:
Interagency Review of Exclusion Order
Enforcement Process
Office of the U.S. Intellectual
Property Enforcement Coordinator,
Executive Office of the President, OMB.
ACTION: Request for written submissions
from the public.
AGENCY:
The Executive Office of the
President, through the U.S. Intellectual
Property Enforcement Coordinator
(‘‘IPEC’’), is beginning an interagency
review directed at strengthening the
procedures and practices used during
enforcement of exclusion orders issued
by the U.S. International Trade
Commission (‘‘ITC’’). The interagency
working group will review existing
procedures that U.S. Customs and
Border Protection (‘‘CBP’’) and the ITC
use to evaluate the scope of exclusion
orders and work to ensure the process
and criteria utilized during exclusion
order enforcement activities are
transparent, effective, and efficient.
Through this request for public
comment, IPEC invites public input and
recommendations in support of the
Administration’s interagency review of
exclusion order enforcement processes
called for by the 2013 Joint Strategic
Plan on Intellectual Property
Enforcement [and the White House Task
Force on High-Tech Patents].
DATES: Submissions must be received on
or before July 21, 2013, at 11:59 p.m.
ADDRESSES: All submissions should be
electronically submitted to https://
www.regulations.gov. If you are unable
to provide submissions to
regulations.gov, you may contact the
Office of the U.S. Intellectual Property
Enforcement Coordinator at
intellectualproperty@omb.eop.gov using
the subject line ‘‘IPEC Review of
Exclusion Order Enforcement
Processes’’ or (202) 395–1808 to arrange
for an alternate method of transmission.
The regulations.gov Web site is a
Federal E-Government Web site that
allows the public to find, review and
submit comments on documents that
have published in the Federal Register
and that are open for comment.
Submissions filed via the
regulations.gov Web site will be
available to the public for review and
inspection. For this reason, please do
not include in your comments
information of a confidential nature,
such as sensitive personal information
or proprietary business information.
FOR FURTHER INFORMATION CONTACT:
Office of the U.S. Intellectual Property
SUMMARY:
[FR Doc. 2013–14458 Filed 6–19–13; 8:45 am]
AGENCY:
OFFICE OF MANAGEMENT AND
BUDGET
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Enforcement Coordinator, at
intellectualproperty@omb.eop.gov or
(202) 395–1808.
SUPPLEMENTARY INFORMATION: Under
Section 337 of the Tariff Act of 1930, the
ITC investigates allegations regarding
unfair practices in import trade,
including allegations related to
intellectual property infringement, as
well as other forms of unfair
competition. Once the ITC finds a
violation of Section 337 and issues an
exclusion order barring the importation
of infringing goods, CBP and the ITC are
responsible for determining whether
imported articles fall within the scope
of the exclusion order. Because of these
shared responsibilities, it is critical that
the ITC and CBP have clear
communication on what the order
means to improve the order’s
enforcement and prevent importation of
infringing product. This determination
can often be challenging, particularly in
cases in which a technologically
sophisticated product may have been
redesigned so as to no longer fall within
the scope of the existing exclusion
order.
IPEC will chair a new interagency
effort directed at strengthening the
processes that CBP uses with regard to
enforcement of ITC exclusion orders
pertaining to intellectual property. The
working group will be comprised of
representatives from the ITC; DHS,
DOC, Treasury, and DOJ; offices within
the Executive Office of the President
including USTR, OSTP, NEC; and other
relevant agencies as necessary.
The interagency working group will
review existing procedures that CBP and
the ITC use to evaluate the scope of ITC
exclusion orders and work to ensure the
process and standards utilized during
exclusion order enforcement activities
are transparent, effective, and efficient.
Among others, one focus of the
interagency review will be on ensuring
that CBP uses transparent and accurate
procedures for determining whether an
article is covered by the ITC exclusion
order. Further, the working group will
evaluate opportunities to improve the
effectiveness of directions provided by
the ITC to assist CBP with the
challenges of enforcement.
Important to the development of the
Administration’s exclusion order
enforcement recommendations, is
ensuring that any approaches that are
considered to be particularly effective as
well as any concerns with the present
approach to exclusion order
enforcement are understood by
policymakers. As such, IPEC is seeking
public input and recommendations
through the questions set out below for
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 78, Number 119 (Thursday, June 20, 2013)]
[Notices]
[Pages 37241-37242]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14458]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Noramco, Inc. (GA)
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 21, 2012, Noramco,
Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application to
the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of Opium tincture (9630), a basic class of controlled
substance listed in schedule II.
The company plans to manufacture the listed controlled substance in
bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance,
[[Page 37242]]
may file comments or objections to the issuance of the proposed
registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administrator, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 19, 2013.
Dated: June 7, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-14458 Filed 6-19-13; 8:45 am]
BILLING CODE 4410-09-P
